2026-06-14T00:35:07Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/266762025-12-18T13:01:01Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19616

00925njm 22002777a 4500 dc Valcárcel-Nazco, Cristina author García-Pérez, Lidia author Linertová, Renata author Guirado-Fuentes, Carmen author Hernández-Yumar, Aránzazu author Paz-Valiñas, Lucinda author Cantero-Muñoz, Paula author Posada De la Paz, Manuel author Serrano-Aguilar, Pedro author 2023-09-13 Newborn screening (NBS) for inherited disorders is recognized as an essential public health intervention to improve health outcomes in the newborn population. The implementation of an NBS programme requires an evaluation of effectiveness, safety, cost-effectiveness, feasibility, and budget impact. Determining which of the known disorders should be included in NBS programmes is a public health policy challenge. In this context, economic evaluation aims to contribute to the sustainability of public health systems, but the appropriate economic evaluation framework for these interventions is still unclear. Existing NBS programmes vary widely in the number and type of disorders screened, even among the most developed European countries, despite the fact that the core criteria for guiding policy decision-making are standard. In Spain, where delivery of NBS programmes is marked by heterogeneity between regions, guidelines based on the best available scientific evidence are being established in order to achieve standardization of NBS policies and programmes at a national level. This paper provides a general overview of existing evidence-based health-policy initiatives aimed at enhancing the equity and efficiency of the NBS programme in Spain and their impact on health decisions. We also describe existing challenges to reduce uncertainty, and the variations observed in decisions relating to the content and procedures used in NBS programmes. Valcárcel-Nazco C, García-Pérez L, Linertová R, Guirado-Fuentes C, Hernández-Yumar A, Paz-Valiñas L, Cantero-Muñoz P, Posada M, Serrano-Aguilar P. Development of newborn screening policies in Spain 2003-2022: what do we actually need to reach an agreement?. Rare Dis Orphan Drugs J. 2023;2:19. 10.20517/rdodj.2023.14 2771-2893 Rare Disease and Orphan Drugs Journal https://hdl.handle.net/20.500.12105/26676 Newborn screening Inherited disorders Health-policy Equity Development of newborn screening policies in Spain 2003-2022: what do we actually need to reach an agreement?